Showing results (21-30 of 39) with videos related to
Sort By:
Pageof 4
BMC Cancer|October 11, 2005
Modeling the effect of age in T1-2 breast cancer using the SEER databasePatricia Tai, Gábor Cserni, Jan Van De Steene, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancerEdgardo Rivera, Vicente Valero, Banu Arun, et al.NPJ Breast Cancer|October 12, 2019
Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristicsCindy K Blair, Charles L Wiggins, Andrea M Nibbe, et al.Breast Cancer Research : BCR|November 13, 2004
Ratios of involved nodes in early breast cancerVincent Vinh-Hung, Claire Verschraegen, Donald I Promish, et al.Breast Cancer Research and Treatment|November 11, 2009
GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancerHugo Arias-Pulido, Melanie Royce, Yun Gong, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Prognostic value of nodal ratios in node-positive breast cancerWendy A Woodward, Vincent Vinh-Hung, Naoto T Ueno, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumorsChristopher J Sweeney, E Gabriela Chiorean, Claire F Verschraegen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancerMassimo Cristofanilli, Vicente Valero, Aroop Mangalik, et al.The Lancet. Oncology|November 19, 2013
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trialAman U Buzdar, Vera J Suman, Funda Meric-Bernstam, et al.The Lancet. Oncology|October 17, 2021
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysisJennifer J Gao, Joyce Cheng, Tatiana M Prowell, et al.Pageof 4